Leeward Investments LLC MA Buys New Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Leeward Investments LLC MA bought a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBHGet Rating) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 102,385 shares of the medical equipment provider’s stock, valued at approximately $13,095,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in ZBH. Motco bought a new stake in Zimmer Biomet in the 1st quarter valued at about $26,000. Cyrus J. Lawrence LLC bought a new stake in Zimmer Biomet in the 1st quarter valued at about $27,000. HHM Wealth Advisors LLC increased its position in Zimmer Biomet by 84.0% in the 1st quarter. HHM Wealth Advisors LLC now owns 219 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 100 shares in the last quarter. FSB Premier Wealth Management Inc. bought a new stake in Zimmer Biomet in the 4th quarter valued at about $33,000. Finally, US Asset Management LLC bought a new stake in Zimmer Biomet during the 1st quarter worth approximately $33,000. 90.34% of the stock is owned by institutional investors.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $113.26 on Friday. Zimmer Biomet Holdings, Inc. has a 12 month low of $100.39 and a 12 month high of $153.76. The company has a current ratio of 1.81, a quick ratio of 0.89 and a debt-to-equity ratio of 0.43. The business’s 50 day simple moving average is $109.35 and its 200 day simple moving average is $117.72. The company has a market cap of $23.76 billion, a price-to-earnings ratio of 103.91, a PEG ratio of 3.37 and a beta of 1.15.

Zimmer Biomet (NYSE:ZBHGet Rating) last posted its earnings results on Tuesday, August 2nd. The medical equipment provider reported $1.82 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.65 by $0.17. The firm had revenue of $1.78 billion for the quarter, compared to the consensus estimate of $1.72 billion. Zimmer Biomet had a return on equity of 12.20% and a net margin of 3.10%. The business’s quarterly revenue was up 1.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.90 earnings per share. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 6.79 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, July 29th. Shareholders of record on Monday, June 27th were given a dividend of $0.24 per share. The ex-dividend date was Friday, June 24th. This represents a $0.96 annualized dividend and a dividend yield of 0.85%. Zimmer Biomet’s dividend payout ratio is currently 88.07%.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Zuilen Wilfred Van sold 531 shares of the stock in a transaction on Tuesday, July 5th. The stock was sold at an average price of $105.22, for a total transaction of $55,871.82. Following the sale, the insider now owns 2,240 shares in the company, valued at $235,692.80. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 0.73% of the company’s stock.

Analyst Ratings Changes

A number of analysts have commented on the company. Stifel Nicolaus decreased their price objective on Zimmer Biomet from $140.00 to $120.00 in a report on Monday, July 18th. Truist Financial decreased their price objective on Zimmer Biomet to $115.00 in a report on Friday, July 22nd. Piper Sandler decreased their price objective on Zimmer Biomet from $130.00 to $120.00 in a report on Tuesday. Morgan Stanley boosted their price objective on Zimmer Biomet from $115.00 to $120.00 and gave the stock an “equal weight” rating in a report on Wednesday. Finally, Needham & Company LLC lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Friday, May 27th. Two analysts have rated the stock with a sell rating, fifteen have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $133.50.

Zimmer Biomet Company Profile

(Get Rating)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T.

Read More

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBHGet Rating).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.